Skip to content

MDMA for anxiety

Studies whose primary subject is both MDMA and Anxiety, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 22 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, Anxiety, generalized anxiety disorder, then ranked by relevance.

The direct trial evidence on MDMA for anxiety is small and mixed: in autistic adults with severe social anxiety, MDMA-assisted psychotherapy produced large, durable reductions in social anxiety relative to placebo, and an open-label waitlist trial in social anxiety disorder reported a very large between-group improvement, but a placebo-controlled trial in people with life-threatening illness found a large though non-significant anxiety reduction (p = .056). Observational and epidemiological data point the other way, linking recreational MDMA use to more anxiety symptoms and higher odds of anxiety disorder. The main caveats are very small samples, open-label or functionally unblinded designs, and the fact that most anxiety findings come from secondary or pilot outcomes.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 24 matching studies were reviewed; the 22 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. 2018 RCT 12 Supports MDMA-assisted psychotherapy produced significantly greater improvement in social anxiety scores than placebo at one month (p = .037, d = 1.4), with similar gains at six months (p = .036, d = 1.1).
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study 2020 RCT 18 Supports MDMA-assisted psychotherapy produced a larger mean reduction in trait anxiety than placebo (−23.5 vs −8.8) with a large effect size (Hedges' g = 1.03), but the group difference did not reach significance (p = .056).
MDMA-Assisted Therapy for Social Anxiety Disorder: A Randomized, Open-label, Wait-list Controlled Trial 2026 RCT (open-label, waitlist-controlled) 20 Supports MDMA-assisted therapy produced a significantly greater reduction in social anxiety than a 16-week waitlist (mean difference −43.3 on the Liebowitz scale, p < .0001, Hedge's g = 2.8), with only mild to moderate transient adverse events.
Therapeutic Alliance and Perceived Closeness in MDMA-Assisted Therapy for Social Anxiety Disorder 2026 secondary analysis of open-label pilot trial 20 Supports Perceived closeness to the therapist rose during each MDMA session and greater session closeness predicted lower post-treatment social anxiety, including after adjustment for pre-session closeness.
Beyond Symptom Reduction: Interconnectedness and Self-Transcendent Emotions During MDMA Sessions Predict Flourishing, Not Symptom Change, in Social Anxiety Disorder Treatment 2026 secondary analysis of randomized waitlist-controlled trial 20 Mixed Connection-oriented self-transcendent experiences during MDMA sessions predicted greater post-treatment belonging, gratitude, and purpose in life but did not predict social anxiety reduction.
The relationship between 3,4-methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid-30s: Findings from the Victorian Adolescent Health Cohort Study. 2025 longitudinal cohort 1943 Opposes MDMA use in early adulthood was associated with higher adjusted odds of an anxiety disorder by the mid-30s, with little evidence of an association with depressive disorders.
Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users 2002 cross-sectional survey 282 Opposes Self-reported anxiety, along with depression, memory, and other problems attributed to ecstasy, increased significantly with the number of lifetime ecstasy use occasions.
Long-Term Neuropsychiatric Consequences of "Ecstasy" (MDMA): A Review 2002 review Opposes Repeated ecstasy use was associated with sleep, mood, and anxiety disturbances, elevated impulsiveness, and memory and attention problems that may persist up to two years after cessation.
Mood state and brain electric activity in Ecstasy users 2000 observational cohort 29 Mixed Ecstasy users showed higher state depressiveness and emotional excitability and a trend-level increase in state anxiety, alongside altered resting EEG power.
No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study 2001 observational cohort Opposes Ecstasy users had significantly higher depressiveness scores than controls despite no differences in regional cerebral blood flow or cognitive task performance.
Gender differences in the subjective effects of MDMA 2001 pooled analysis of three double-blind placebo-controlled studies 74 Mixed Women reported more intense psychoactive effects, including thought disturbances and fear of loss of body control, and more acute adverse effects than men, while men showed greater blood pressure increases.
A review of the acute subjective effects of MDMA/ecstasy 2006 systematic review Mixed Acute subjective effects of MDMA most often reported across studies were emotional (including anxiety, fear, and calmness) or somatic, with dose, time since ingestion, and gender associated with the experience.
3,4-Methylenedioxymethamphetamine facilitates fear extinction learning 2015 preclinical experimental study Supports MDMA administered before extinction training persistently enhanced long-term fear extinction, an effect recapitulated by direct infusion into the basolateral amygdala and abolished when BDNF signaling was inhibited.
MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear. 2026 experimental study in an animal model 210 Supports Repeated low doses of MDMA or psilocybin reduced anxiety-like behavior in fear-conditioned rats, and disrupting myelin abolished these anxiolytic effects.
A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats 2026 experimental study Mixed Repeated low-dose MDMA produced mild anxiety-like behavior and reduced nucleus accumbens serotonin one day after exposure, but anxiety-like behavior was unaffected at 15 days.
How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale 2009 theoretical Supports Argues that MDMA-augmented psychotherapy may treat treatment-resistant anxiety disorders through increased oxytocin, altered prefrontal and amygdala activity, and elevated norepinephrine and cortisol that facilitate fear extinction.
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. 2016 review 1133 Supports Argues that MDMA has been administered to over 1133 research participants without unexpected drug-related serious adverse events, and that infrequent dosing may offer a favorable risk/benefit ratio for social anxiety in autistic adults.
MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions 2025 review Supports Reports that early randomized placebo-controlled studies suggest benefits of MDMA-assisted psychotherapy in autism spectrum disorder and anxiety related to life-threatening illness, while noting regulatory delays over functional unblinding and protocol rigor.
Ecstasy (MDMA) for social anxiety in autism: a specialized application of empathogen therapy 2026 narrative review / commentary Supports Argues that MDMA-assisted psychotherapy reduces social fear and anxiety in autistic adults in a pilot trial but that larger safety trials are needed.
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses 2020 review Supports Reports that accumulated research suggests psychedelics including MDMA may become breakthrough therapies for psychiatric conditions refractory to conventional treatment, including end-of-life anxiety, while requiring safeguards against misuse.
Clinical applications of hallucinogens: A review. 2016 review Supports Argues that a growing body of evidence indicates hallucinogens including entactogens such as MDMA may have therapeutic applications beyond their potential for abuse.
Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder 2026 study protocol Unclear Describes a planned study to test whether trait and session-level self-compassion increase during MDMA-assisted therapy and mediate changes in social anxiety and related outcomes.

Points of agreement

  • Controlled and open-label trials in social anxiety (autistic adults and social anxiety disorder) consistently report large reductions in social anxiety after MDMA-assisted psychotherapy.
  • The life-threatening-illness trial also favored MDMA over placebo on anxiety, with a large effect size, though it fell just short of significance.
  • Preclinical work supports a mechanistic rationale: MDMA enhances fear extinction and reduces anxiety-like behavior in rodents, dependent on BDNF and myelin integrity.
  • Reviews and theoretical papers converge on the view that infrequent MDMA dosing combined with psychotherapy may offer a favorable risk/benefit profile for anxiety-related conditions.
  • Observational studies of recreational users consistently associate more extensive ecstasy use with more anxiety and depressive symptoms.

Conflicts

  • Clinical trial results (anxiety improves with MDMA-assisted therapy) run opposite to observational and epidemiological findings (recreational MDMA use associated with more anxiety and higher odds of anxiety disorder).
  • One trial's anxiety reduction missed statistical significance despite a large effect size, while another reported a very large significant effect, so the strength of the clinical signal is inconsistent across trials.
  • Within-session self-transcendent connection experiences predicted wellbeing but not social anxiety reduction, whereas therapist closeness did predict lower social anxiety.
  • Rodent data are mixed on acute anxiogenic effects: one study found transient anxiety-like behavior at one day, another found anxiolytic effects with repeated low doses.

Gaps

  • Very small samples (12-20 participants) in all anxiety trials, with wide confidence intervals.
  • Blinding is a major concern: one trial was open-label waitlist-controlled, and reviews flag functional unblinding in MDMA trials generally.
  • Durability beyond 6-12 months is largely unexamined, and long-term follow-up data are sparse.
  • Dose-finding is absent; trials used differing regimens (75-125 mg, 125 mg, two versus three sessions).
  • Populations studied are narrow (autistic adults, social anxiety disorder, life-threatening illness), with little data on other anxiety disorders, older adults, or diverse demographic groups.
  • Most anxiety findings are secondary or pilot outcomes rather than adequately powered primary endpoints.
Browse these studies in the library

Common questions

What does the research agree on about MDMA for anxiety?
  • Controlled and open-label trials in social anxiety (autistic adults and social anxiety disorder) consistently report large reductions in social anxiety after MDMA-assisted psychotherapy.
  • The life-threatening-illness trial also favored MDMA over placebo on anxiety, with a large effect size, though it fell just short of significance.
  • Preclinical work supports a mechanistic rationale: MDMA enhances fear extinction and reduces anxiety-like behavior in rodents, dependent on BDNF and myelin integrity.
  • Reviews and theoretical papers converge on the view that infrequent MDMA dosing combined with psychotherapy may offer a favorable risk/benefit profile for anxiety-related conditions.
  • Observational studies of recreational users consistently associate more extensive ecstasy use with more anxiety and depressive symptoms.
Where do studies on MDMA for anxiety conflict?
  • Clinical trial results (anxiety improves with MDMA-assisted therapy) run opposite to observational and epidemiological findings (recreational MDMA use associated with more anxiety and higher odds of anxiety disorder).
  • One trial's anxiety reduction missed statistical significance despite a large effect size, while another reported a very large significant effect, so the strength of the clinical signal is inconsistent across trials.
  • Within-session self-transcendent connection experiences predicted wellbeing but not social anxiety reduction, whereas therapist closeness did predict lower social anxiety.
  • Rodent data are mixed on acute anxiogenic effects: one study found transient anxiety-like behavior at one day, another found anxiolytic effects with repeated low doses.
What is still unknown about MDMA for anxiety?
  • Very small samples (12-20 participants) in all anxiety trials, with wide confidence intervals.
  • Blinding is a major concern: one trial was open-label waitlist-controlled, and reviews flag functional unblinding in MDMA trials generally.
  • Durability beyond 6-12 months is largely unexamined, and long-term follow-up data are sparse.
  • Dose-finding is absent; trials used differing regimens (75-125 mg, 125 mg, two versus three sessions).
  • Populations studied are narrow (autistic adults, social anxiety disorder, life-threatening illness), with little data on other anxiety disorders, older adults, or diverse demographic groups.
  • Most anxiety findings are secondary or pilot outcomes rather than adequately powered primary endpoints.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA for anxiety, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when MDMA for anxiety or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

95 articles · 18 from the last two years · 7,908 participants across 44 studies reporting sample size

Common study designs

review 26 case study 5 systematic review 6 observational cohort 5 randomized controlled trial 10

Research volume by year

Compare topics →

88 studies whose primary subject is MDMA for anxiety since 2002

Studies about MDMA for anxiety per year, 2002 to 2026, peaking at 12 in 2023 Bar chart: one bar per year, taller where more studies were published that year. 0 10 20 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about MDMA for anxiety per year, 2002 to 2026, peaking at 12 in 2023
Year Studies
2002 2
2003 0
2004 1
2005 0
2006 4
2007 2
2008 1
2009 1
2010 2
2011 0
2012 0
2013 1
2014 3
2015 2
2016 4
2017 5
2018 4
2019 2
2020 2
2021 8
2022 8
2023 12
2024 6
2025 9
2026 9

Research

Synthesize the evidence →

From Acute MDMA Experiences to Lasting Change: Self-Compassion’s Role in MDMA-Assisted Psychotherapy for Social Anxiety Disorder

October 25, 2026 Christina Chwyl, Mary K. Lear, Sunjeev K. Kamboj et al. preprint

Objectives: Self-compassion may benefit individuals with social anxiety disorder and serve as a mechanism of change within 3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT). Methods: In this secondary analysis of 20 adults with social anxiety disorder who underwent MDMA-AT for social anxiety disorder (NCT05138068), we examined whether both trait self-compassion changes across...

DOI: 10.31234/osf.io/3ard8_v1 (opens in new tab)

Beyond Symptom Reduction: Interconnectedness and Self-Transcendent Emotions During MDMA Sessions Predict Flourishing, Not Symptom Change, in Social Anxiety Disorder Treatment

October 20, 2026 Christina Chwyl, Mary K. Lear, Jason B. Luoma preprint

By fostering certain self-transcendent experiences (STE)—those characterized by interconnectedness and other-oriented emotions—3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has been hypothesized to disrupt social anxiety disorder maintenance processes, including negative self-focus, self-criticism, and isolation, thereby enhancing wellbeing. This secondary analysis used...

DOI: 10.31234/osf.io/kbxdq_v1 (opens in new tab)

Therapeutic Alliance and Perceived Closeness in MDMA-Assisted Therapy for Social Anxiety Disorder

September 11, 2026 Joseph M. Diehl, Christina Chwyl, Liliana Kennedy et al. preprint

The therapeutic relationship is considered central to psychedelic-assisted therapy, yet little empirical research has examined how it changes during 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) or relates to acute MDMA experiences and clinical outcomes, particularly for social anxiety disorder (SAD). This preregistered secondary analysis examined therapeutic alliance and...

DOI: 10.31234/osf.io/tezgw_v1 (opens in new tab)

MDMA-Assisted Therapy for Social Anxiety Disorder: A Randomized, Open-label, Wait-list Controlled Trial

June 4, 2026 Jason B. Luoma, M. Kati Lear, Brian Pilecki et al. preprint

Background: ±3,4-methylenedioxymethamphetamine (MDMA) has positive effects on socio-emotional processing and MDMA-Assisted Therapy (MDMA-AT) showed promise for treating SAD in a previous placebo-controlled trial. Aims: Develop a preliminary estimate of clinical response and safety for MDMA-AT versus waitlist in adults with SAD. Secondary aims included refinement of a standardized psychotherapy...

DOI: 10.31234/osf.io/a9x6d_v1 (opens in new tab) Social anxiety Randomized controlled trial Adverse effect Clinical trial +3

Ecstasy (MDMA) for social anxiety in autism: a specialized application of empathogen therapy

Annals of Medicine and Surgery April 6, 2026 Mahnoor Sheikh, Zaibunnisa Bilal, Syeda Habiba Fatima et al.

To the Editor, Autism spectrum disorder (ASD) is a neurodevelopmental state in which there are early emerging problems in social communication along with fixed behavior patterns. Social difficulties in ASD are characterized by difficulty in interpretation of interpersonal signals such as facial expressions, tone of voice, and body language. Individuals with ASD often present with social...

DOI: 10.1097/ms9.0000000000004936 (opens in new tab) Ecstasy Social anxiety Social skills Social inhibition +14

A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats

Psychopharmacology March 4, 2026 Ava M. Mac, Srinivasu Kallakuri, Alixandria T. Mascarin et al.

MDMA (3–4 methylenedioxymethamphetamine) assisted psychotherapy has gained considerable attention as a potential adjuvant therapy for post-traumatic stress disorder (PTSD). Reports of the nonmedical use of MDMA suggest its adverse effects may include anxiety and anhedonia. However, the time course of these signs and symptoms and the potential alterations in neurotransmitter levels that may...

DOI: 10.1007/s00213-026-07010-1 (opens in new tab) Full text (opens in new tab) MDMA Serotonin Serotonergic Monoamine neurotransmitter +13

MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear.

Biological Psychiatry February 3, 2026 Mehmet Bostancıklıoğlu, Davut Sinan Kaplan, Ramazan Bal et al.

Psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) produce rapid, enduring therapeutic effects in post-traumatic stress disorder (PTSD); however, the underlying cellular mechanisms remain incompletely understood. This study investigated whether adult myelin plasticity contributes to the therapeutic actions of psilocybin and MDMA in a rat model of contextual fear conditioning. Adult male...

DOI: 10.1016/j.biopsych.2026.01.016 (opens in new tab) Full text (opens in new tab) MDMA Psilocybin Fear-related behaviors Myelination +2

Partydrogen im Überblick

Psychopharmakotherapie 2026 Antonia Bendau, Felix Betzler, Twyla Michnevich et al. 1 citation

Party drugs encompass a broad spectrum of legal and illegal psychoactive substances used in party settings such as clubs, festivals, raves or private gatherings to modulate mood, perception, social interaction and bodily states. Most commonly, alcohol and cannabis are consumed, followed by amphetamine, MDMA (“ecstasy”), cocaine and ketamine. Synthetic cathinones, GHB/GBL (“liquid ecstasy”),...

DOI: 10.52778/ppt20260001 (opens in new tab) Serotonergic MDMA Addiction Cannabis +16

Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder

Open Science Framework 2026 Christina Chwyl, M. Kati Lear, Sunjeev K. Kamboj et al. preprint

Self-compassion is theorized to play a central role in promoting mental health and wellbeing, including for individuals with social anxiety disorder (SAD). One proposed mechanism of MDMA-assisted therapy (MDMA-AT) for SAD is the cultivation of self-compassion. Across five aims, we will characterize self-compassion experiences during MDMA-AT and evaluate its role as a potential mechanism of...

DOI: 10.17605/osf.io/p8du5 (opens in new tab) Major depressive disorder Social anxiety Dosing Mechanism biology +5

The relationship between 3,4-methylenedioxymethamphetamine (MDMA) use in young adulthood and anxiety or depressive disorders in the mid-30s: Findings from the Victorian Adolescent Health Cohort Study.

Addiction December 1, 2025 Zachary Bryant, Kirsten Morley, Jessica A Kerr et al.

MDMA (3,4-methylenedioxymethamphetamine or "Ecstasy") is the fourth-most used illicit substance globally. While previous research found links between MDMA use and mental health outcomes, the direction and nature of this relationship remain unclear. This study assessed whether MDMA use in early adulthood increases the risk of anxiety or depression in mid-30s. A longitudinal, population-based...

DOI: 10.1111/add.70173 (opens in new tab) Full text (opens in new tab) MDMA Anxiety Depression 3,4‐methylenedioxymethamphetamine +5

Clinical trials

All mdma for anxiety trials →